# Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

> **NCT04304508** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 1808 (actual)

## Conditions studied

- Acute Non-cardioembolic Ischemic Stroke

## Interventions

- **DRUG:** BAY2433334
- **OTHER:** BAY2433334 matching placebo

## Key facts

- **NCT ID:** NCT04304508
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-15
- **Primary completion:** 2022-02-18
- **Final completion:** 2022-02-18
- **Target enrollment:** 1808 (ACTUAL)
- **Last updated:** 2023-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04304508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04304508, "Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04304508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*